A Phase II Trial of MK-3475 (Pembrolizumab) and Interferon Gamma 1-b Combination Immunotherapy in Patients With Previously Treated Mycosis Fungoides and Sezary Syndrome (Treatment Group 1) and in Patients With Advanced Synovial Sarcoma (Treatment Group 2)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Interferon gamma-1b (Primary) ; Pembrolizumab (Primary)
Indications Mycosis fungoides; Myxoid liposarcoma; Sezary syndrome; Synovial sarcoma
Focus Therapeutic Use

Most Recent Events

03 Oct 2023 Status changed from active, no longer recruiting to completed.
20 Jul 2023 Planned End Date changed from 8 Apr 2023 to 8 Apr 2024.
02 Aug 2022 Planned End Date changed from 8 Apr 2022 to 8 Apr 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight